Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Extension Study of RVT-101 in Subjects with Alzheimer's Disease
2016-000587-42Phase 3Terminated
- Sponsor
- Sio Gene Therapies
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of intepirdine in Alzheimer's disease (AD), sponsored by Sio Gene Therapies. Primary endpoints: Incidence of adverse events, Changes in physical examinations and 4 more. Started Jun 2016; status: terminated.
02
Drugs
intepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-000587-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000587-42.